Camilla Krogh Lauritzen, MSc MCC MMBA is the European Lead Patient Advocacy at Orphazyme & Partner at NGOtiate.

Before joining Orphazyme and NGOtiate, Camilla was the Chief Patient Officer and Head of Patient Engagement at LEO Pharma, being responsible for all strategic and operational patient engagement activities in the company. Anchored in the Research organization at LEO Pharma, her team was responsible for driving key deliveries to LEO´s 2025 strategy that targeted development of interventions against some of the world’s most painful and life-threatening genetic and autoimmune diseases for which no treatment or cure currently exist.

Prior to joining LEO in May 2018, she established and led the Patient Engagement function at Abbott, AbbVie and Novo Nordisk. Before that, she worked for science/patient alliances and for patient organizations.

She holds a Master degree in Molecular Biology, Corporate Communication and Business Administration.

LinkedIn

 

Terms on SAB

  • 1st term (2021-2022)